Yuki Kageyama to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Yuki Kageyama has written about Antineoplastic Agents, Immunological.
Connection Strength
0.414
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.
Score: 0.210
-
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Med. 2020 11; 9(22):8355-8363.
Score: 0.163
-
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021 Mar; 70(3):657-665.
Score: 0.041